AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19164458 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET metabolic response
Number of subjects: 51
Study 17556905 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin (25 mg)
Number of subjects: 10
Study 17556905 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (80 mg)
Number of subjects: 10
Study 17556905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15219652 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental loss by death (n=9)
Number of subjects: 57
Study 15219652 — intervention group
Group type: COMPARATOR
Intervention: No parental loss or separation (n=38)
Number of subjects: 57
Study 15219652 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary separation from one or both parents (n=10)
Number of subjects: 57
Study 12365877 — intervention group
Group type: EXPERIMENTAL
Intervention: High lifetime panic-agoraphobic spectrum symptom scores
Number of subjects: 66
Study 12365877 — intervention group
Group type: COMPARATOR
Intervention: Low lifetime panic-agoraphobic spectrum symptom scores
Number of subjects: 66
Study 11693763 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidapril (n = 13)
Number of subjects: 25
Study 11693763 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (n = 12)
Number of subjects: 25
Study 11693763 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidapril
Number of subjects: 25
Study 11693763 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 25
Study 9307551 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 0
Study 9307551 — intervention group
Group type: COMPARATOR
Intervention: No surgery
Number of subjects: 0
Study 8325064 — intervention group
Group type: COMPARATOR
Intervention: Nebulized morphine 0 mg
Number of subjects: 8
Study 8325064 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized morphine 1 mg
Number of subjects: 8
Study 8325064 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized morphine 4 mg
Number of subjects: 8
Study 8325064 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized morphine 10 mg
Number of subjects: 8
Study 2876127 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 1% eye drops
Number of subjects: 0
Study 2876127 — intervention group
Group type: EXPERIMENTAL
Intervention: Metipranolol 0.6% eye drops
Number of subjects: 0
Study 30539864 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent 125I implantation and chemotherapy
Number of subjects: 82
Study 30539864 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy-only
Number of subjects: 82
Study 27058904 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) treatment
Number of subjects: 0
Study 27058904 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 25027638 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitors in HIV-positive patients with lipodystrophy syndrome
Number of subjects: 267
Study 25027638 — intervention group
Group type: COMPARATOR
Intervention: HIV-negative patients without lipodystrophy syndrome
Number of subjects: 267
Study 25027638 — intervention group
Group type: COMPARATOR
Intervention: HIV-positive patients not using protease inhibitors
Number of subjects: 267
Study 25027638 — intervention group
Group type: COMPARATOR
Intervention: HIV-positive patients treated with protease inhibitors but without posterior ankle pain
Number of subjects: 267
Study 22154039 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management-family engagement (CM-FAM)
Number of subjects: 104
Study 22154039 — intervention group
Group type: COMPARATOR
Intervention: Usual services (US)
Number of subjects: 104
Study 20547525 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum screening for type 2 diabetes (T2DM) via oral glucose tolerance tests (OGTTs)
Number of subjects: 223
Study 20547525 — intervention group
Group type: COMPARATOR
Intervention: Postpartum screening for T2DM by primary care providers (PCPs)
Number of subjects: 223
Study 20547525 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder letters for facilitating screening
Number of subjects: 223
Study 20547525 — intervention group
Group type: EXPERIMENTAL
Intervention: Importance of screening for T2DM
Number of subjects: 223
Study 20547525 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsibility for screening
Number of subjects: 223
Study 18713922 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (TDN) 30 (21 mg nicotine) patches administered 1 h before induction of anesthesia and for two additional days after surgery
Number of subjects: 97
Study 18713922 — intervention group
Group type: COMPARATOR
Intervention: Inert (sham) patches administered 1 h before and for 2 days after surgery
Number of subjects: 97
Study 18713922 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (nicotine and control)
Number of subjects: 97
Study 18713922 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine group
Number of subjects: 97
Study 16296612 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% SDBS ointment
Number of subjects: 62
Study 16296612 — intervention group
Group type: COMPARATOR
Intervention: 2% metronidazole ointment
Number of subjects: 62
Study 12675669 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg glibenclamide
Number of subjects: 10
Study 12675669 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg diazoxide
Number of subjects: 10
Study 12675669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10355239 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxed decision criteria
Number of subjects: 0
Study 10355239 — intervention group
Group type: COMPARATOR
Intervention: Standard decision criteria
Number of subjects: 0
Study 10182204 — intervention group
Group type: EXPERIMENTAL
Intervention: Batch sampling method
Number of subjects: 0
Study 10182204 — intervention group
Group type: EXPERIMENTAL
Intervention: Community endpoint means stability
Number of subjects: 0
Study 10182204 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal variation
Number of subjects: 0
Study 2022044 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine echocardiography
Number of subjects: 35
Study 2022044 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole echocardiography
Number of subjects: 35
Study 31770068 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccine Lot 1
Number of subjects: 3689
Study 31770068 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccine Lot 2
Number of subjects: 3689
Study 31770068 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccine Lot 3
Number of subjects: 3689
Study 31268126 — intervention group
Group type: EXPERIMENTAL
Intervention: Broccoli sprout beverage (full dose, n=25)
Number of subjects: 170
Study 31268126 — intervention group
Group type: EXPERIMENTAL
Intervention: Broccoli sprout beverage (one-half dose, n=35)
Number of subjects: 170
Study 31268126 — intervention group
Group type: EXPERIMENTAL
Intervention: Broccoli sprout beverage (one-fifth dose, n=55)
Number of subjects: 170
Study 31268126 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage (n=55)
Number of subjects: 170
Study 28146026 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 75
Study 28146026 — intervention group
Group type: COMPARATOR
Intervention: Conventional neck exercises
Number of subjects: 75
Study 28146026 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 75
Study 26102255 — intervention group
Group type: EXPERIMENTAL
Intervention: External focus (EX)
Number of subjects: 68
Study 26102255 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad internal focus (B-IN)
Number of subjects: 68
Study 26102255 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow internal focus (N-IN)
Number of subjects: 68
Study 26102255 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 68
Study 24553678 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injections into the subscapularis muscle
Number of subjects: 36
Study 24553678 — intervention group
Group type: COMPARATOR
Intervention: Scapulothoracic bursa injections
Number of subjects: 36
Study 23107861 — intervention group
Group type: EXPERIMENTAL
Intervention: Meaning of Life Intervention
Number of subjects: 84
Study 23107861 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study 19751376 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 70
Study 19751376 — intervention group
Group type: COMPARATOR
Intervention: Theophylline
Number of subjects: 70
Study 19751376 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (combined treatment plus prophylaxis)
Number of subjects: 70
Study 19751376 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline and Caffeine (both)
Number of subjects: 70
Study 17521032 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg of hydrofluoroalkane beclomethasone dipropionate via the Neohaler (NH)
Number of subjects: 17
Study 17521032 — intervention group
Group type: COMPARATOR
Intervention: 100 microg of hydrofluoroalkane beclomethasone dipropionate via the AeroChamber Plus (AP)
Number of subjects: 17
Study 17521032 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg of hydrofluoroalkane beclomethasone dipropionate via the Neohaler (NH)
Number of subjects: 17
Study 17521032 — intervention group
Group type: COMPARATOR
Intervention: 400 microg of hydrofluoroalkane beclomethasone dipropionate via the AeroChamber Plus (AP)
Number of subjects: 17
Study 17521032 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro fine particle dose for Neohaler (NH) with 100-microg formulation
Number of subjects: 17
Study 17521032 — intervention group
Group type: COMPARATOR
Intervention: In vitro fine particle dose for AeroChamber Plus (AP) with 100-microg formulation
Number of subjects: 17
Study 17521032 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro fine particle dose for Neohaler (NH) with 50-microg formulation
Number of subjects: 17
Study 17521032 — intervention group
Group type: COMPARATOR
Intervention: In vitro fine particle dose for AeroChamber Plus (AP) with 50-microg formulation
Number of subjects: 17
Study 15209624 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin + eradication (omeprazole 20 mg b.i.d. and amoxicillin 500 mg q.i.d. for 2 weeks)
Number of subjects: 32
Study 15209624 — intervention group
Group type: COMPARATOR
Intervention: Aspirin + placebo eradication
Number of subjects: 32
Study 11685360 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation (16 physiotherapeutic exercises for 8 weeks)
Number of subjects: 40
Study 11685360 — intervention group
Group type: COMPARATOR
Intervention: Knee splint (special resistance-controlled knee splint for 15 min three times daily)
Number of subjects: 40
Study 9588444 — intervention group
Group type: EXPERIMENTAL
Intervention: ICA512 autoantibodies
Number of subjects: 152
Study 9588444 — intervention group
Group type: EXPERIMENTAL
Intervention: phogrin autoantibodies
Number of subjects: 152
Study 9588444 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramolecular epitope spreading
Number of subjects: 152
Study 9588444 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in number of epitopes recognized
Number of subjects: 152
Study 7975843 — intervention group
Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb (EZ) virus at age 4-8 months (medium dose: 40,000 p.f.u. and high dose: 150,000 p.f.u.)
Number of subjects: 362
Study 7975843 — intervention group
Group type: COMPARATOR
Intervention: Schwarz (SW) virus at age 9-12 months (standard dose: 5000 p.f.u.)
Number of subjects: 362
Study 2644342 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 30
Study 2644342 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine 75 mg/day
Number of subjects: 30
Study 800970 — intervention group
Group type: EXPERIMENTAL
Intervention: tolmetin (1600 mg/day)
Number of subjects: 24
Study 800970 — intervention group
Group type: EXPERIMENTAL
Intervention: phenylbutazone (400 mg/day)
Number of subjects: 24
Study 31310038 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopy-guided axillary vein access
Number of subjects: 240
Study 31310038 — intervention group
Group type: COMPARATOR
Intervention: Cephalic vein access
Number of subjects: 240
Study 28619301 — intervention group
Group type: EXPERIMENTAL
Intervention: Gua sha
Number of subjects: 0
Study 28619301 — intervention group
Group type: COMPARATOR
Intervention: Hydrocollator-based hot pack therapy (active control)
Number of subjects: 0
Study 24801108 — intervention group
Group type: EXPERIMENTAL
Intervention: Written emotional disclosure (WED)
Number of subjects: 41
Study 24801108 — intervention group
Group type: COMPARATOR
Intervention: Neutral writing (control)
Number of subjects: 41
Study 23860345 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐MPH‐ER 30 mg
Number of subjects: 165
Study 23860345 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐MPH‐ER 20 mg
Number of subjects: 165
Study 23860345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 21722499 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept approximately 10 mg/kg
Number of subjects: 108
Study 19801244 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional irrigation with NaviTip needles (20 mL NaOCl and EDTA)
Number of subjects: 60
Study 19801244 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional irrigation with NaviTip needles + EndoActivator (20 mL NaOCl and EDTA)
Number of subjects: 60
Study 19801244 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigation with EndoVac system (43 mL NaOCl and EDTA)
Number of subjects: 60
Study 19801244 — intervention group
Group type: COMPARATOR
Intervention: Control group with saline solution (43 mL)
Number of subjects: 60
Study 16677241 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 0
Study 16677241 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 0
Study 15093801 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer sexual health education intervention
Number of subjects: 416
Study 10779265 — intervention group
Group type: EXPERIMENTAL
Intervention: High inositol formula (2500 micromol/L)
Number of subjects: 0
Study 10779265 — intervention group
Group type: COMPARATOR
Intervention: Lower inositol formula (710 and 242 micromol/L)
Number of subjects: 0
Study 9313749 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy (ultralente)
Number of subjects: 8
Study 9313749 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylurea therapy (gliclazide)
Number of subjects: 8
Study 9313749 — intervention group
Group type: COMPARATOR
Intervention: Diet therapy
Number of subjects: 8
Study 8376739 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum vaccine
Number of subjects: 100
Study 8376739 — intervention group
Group type: COMPARATOR
Intervention: Recombinant vaccine
Number of subjects: 100
Study 8376739 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined regimen (serum and recombinant vaccines)
Number of subjects: 100
Study 8376739 — intervention group
Group type: COMPARATOR
Intervention: Three doses of serum-derived vaccine
Number of subjects: 100
Study 3511409 — intervention group
Group type: EXPERIMENTAL
Intervention: K‐canrenoate
Number of subjects: 90
Study 3511409 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone
Number of subjects: 90
Study 31242333 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally Advanced Flap (CAF)
Number of subjects: 19
Study 31242333 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunnel technique (TUN)
Number of subjects: 19
Study 28667207 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional intervention based on individual patient-reported outcomes (PROs) including electronic assessment of PRO, creation of a case vignette, and treatment suggestions from expert panel discussions.
Number of subjects: 0
Study 28667207 — intervention group
Group type: COMPARATOR
Intervention: Usual supportive treatment.
Number of subjects: 0
Study 26137844 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS-text adherence support intervention
Number of subjects: 15
Study 24065808 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrysof Natural IQ IOLs
Number of subjects: 30
Study 24065808 — intervention group
Group type: COMPARATOR
Intervention: Adapt‐AO IOLs
Number of subjects: 30
Study 21735983 — intervention group
Group type: EXPERIMENTAL
Intervention: Menopausal symptoms awareness
Number of subjects: 100
Study 21735983 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of means to mitigate symptoms
Number of subjects: 100
Study 21735983 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of soya and soya-based supplements
Number of subjects: 100
Study 19663113 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinonide 0.1% cream
Number of subjects: 5
Study 19663113 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol 0.05% cream
Number of subjects: 5
Study 19663113 — intervention group
Group type: EXPERIMENTAL
Intervention: Halobetasol 0.05% cream
Number of subjects: 5
Study 19663113 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 5
Study 16784972 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 2659
Study 16784972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2659
Study 15121348 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention
Number of subjects: 533
Study 15121348 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients taking ADs
Number of subjects: 533
Study 15121348 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 533
Study 11245352 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple dose IVIG treatment
Number of subjects: 61
Study 11245352 — intervention group
Group type: COMPARATOR
Intervention: Single dose MG treatment
Number of subjects: 61
Study 11245352 — intervention group
Group type: COMPARATOR
Intervention: No IVIG treatment (Control group)
Number of subjects: 61
Study 9399606 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 17
Study 9399606 — intervention group
Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 17
Study 8181191 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ketoconazole orally once daily for 4 days
Number of subjects: 9
Study 8181191 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg itraconazole orally once daily for 4 days
Number of subjects: 9
Study 8181191 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo orally once daily for 4 days
Number of subjects: 9
Study 8181191 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg midazolam administered on day 4
Number of subjects: 9
Study 3371079 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid (500 mg 3-times daily)
Number of subjects: 30
Study 3371079 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam (20 mg single daily dose)
Number of subjects: 30
Study 30565543 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive impairment
Number of subjects: 1469
Study 30565543 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementing illnesses
Number of subjects: 1469
Study 30565543 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium
Number of subjects: 1469
Study 30565543 — intervention group
Group type: EXPERIMENTAL
Intervention: No cognitive impairment
Number of subjects: 1469
Study 30565543 — intervention group
Group type: EXPERIMENTAL
Intervention: Documented diagnosis of dementia
Number of subjects: 1469
Study 30565543 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for dehydration, electrolyte disturbances, urinary tract infections, contusions, and bone fractures
Number of subjects: 1469
Study 26525521 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (initial dose of 180 mg and maintenance dose of 90 mg twice daily, n = 149)
Number of subjects: 300
Study 26525521 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (initial dose of 300 mg and maintenance dose of 75 mg once daily, n = 151)
Number of subjects: 300
Study 26525521 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 300
Study 26525521 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 300
Study 23877306 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual midazolam 0.25 mg/kg
Number of subjects: 100
Study 23877306 — intervention group
Group type: COMPARATOR
Intervention: Sublingual dexmedetomidine 1.5 µg/kg
Number of subjects: 100
Study 22275399 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 μg HA 2009 H1N1 vaccine
Number of subjects: 192
Study 22275399 — intervention group
Group type: COMPARATOR
Intervention: 15 μg HA 2009 H1N1 vaccine
Number of subjects: 192
Study 20737140 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibandronate (2.5 mg daily, 20 mg intermittent)
Number of subjects: 2
Study 20737140 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ibandronate (0.5 mg, 1 mg quarterly)
Number of subjects: 2
Study 20737140 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled analysis of ibandronate
Number of subjects: 2
Study 18276620 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 228
Study 18276620 — intervention group
Group type: EXPERIMENTAL
Intervention: MFP
Number of subjects: 228
Study 18276620 — intervention group
Group type: EXPERIMENTAL
Intervention: E/Ea
Number of subjects: 228
Study 18276620 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated NT-proBNP and E/Ea >15
Number of subjects: 228
Study 18276620 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of NT-proBNP and E/Ea
Number of subjects: 228
Study 16322625 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative management
Number of subjects: 0
Study 16322625 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative management
Number of subjects: 0
Study 11437014 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20-40 mg)
Number of subjects: 275
Study 11437014 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (200-300 mg)
Number of subjects: 275
Study 11437014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275
Study 11437014 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 275
Study 11437014 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 275